The survival of GL261 glioma tumor-bearing mice increased [117], suggesting that disrupting the binding between CD200 and its receptor, CD200R, can potentially enhance the efficacy of an immune-mediated antitumor approach for brain tumors. This evidence concerns the gene CD200 and brain neoplasm.